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Background: GWAS have consistently revealed that LDLR locus variability influences LDL-cholesterol in general
population. Severe LDLR mutations are responsible for familial hypercholesterolemia (FH). However, most primary
hypercholesterolemias are polygenic diseases. Although Cis-regulatory regions might be the cause of LDL-cholesterol
variability; an extensive analysis of the LDLR distal promoter has not yet been performed. We hypothesized that genetic
variants in this region are responsible for the LDLR association with LDL-cholesterol found in GWAS.
Methods: Four-hundred seventy-seven unrelated subjects with polygenic hypercholesterolemia (PH) and without
causative FH-mutations and 525 normolipemic subjects were selected. A 3103 pb from LDLR (−625 to +2468) was
sequenced in 125 subjects with PH. All subjects were genotyped for 4 SNPs (rs17242346, rs17242739, rs17248720 and
rs17249120) predicted to be potentially involved in transcription regulation by in silico analysis. EMSA and luciferase
assays were carried out for the rs17248720 variant. Multivariable linear regression analysis using LDL-cholesterol levels
as the dependent variable were done in order to find out the variables that were independently associated with
LDL-cholesterol.
Results: The sequencing of the 125 PH subjects did not show variants with minor allele frequency≥ 10%. The T-allele
from g.3131C > T (rs17248720) had frequencies of 9% (PH) and 16.4% (normolipemic), p < 0.00001. Studies of this
variant with EMSA and luciferase assays showed a higher affinity for transcription factors and an increase of 2.5 times in
LDLR transcriptional activity (T-allele vs C-allele). At multivariate analysis, this polymorphism with the lipoprotein(a) and
age explained≈ 10% of LDL-cholesterol variability.
Conclusion: Our results suggest that the T-allele at the g.3131 T > C SNP is associated with LDL-cholesterol levels,
and explains part of the LDL-cholesterol variability. As a plausible cause, the T-allele produces an increase in LDLR
transcriptional activity and lower LDL-cholesterol levels.
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Hypercholesterolemia due to high plasma levels of low-
density lipoprotein cholesterol (LDL-C) is the main risk
factor for cardiovascular diseases. The individual con-
centration of LDL-C depends on the interplay between
genetic and environmental factors. Severe primary hyper-
cholesterolemias are often monogenic disorders, such as
familial hypercholesterolemia (FH) associated with muta-
tions in coding regions of LDLR, APOB, or PCSK9 genes
[1-4]. However, no functional defects are detected in these
genes in most subjects with primary hypercholesterol-
emia, albeit, in comparison with FH, a milder pheno-
type and lower family penetrance are usually present.
Actually, most of these subjects receive a diagnosis of
polygenic hypercholesterolemia (PH), and it is believed
that common genetic variants in the population are re-
sponsible for this phenotype [5]. It has been recently
published that a substantial number of subjects with FH
without a known mutation have increased the number of
polymorphisms associated with higher LDL-C levels, there-
fore they might have a polygenic cause [6,7].
Several Genome Wide Association Studies (GWAS)
carried out during the past decade have revealed that
variability at the LDLR locus is associated with LDL-C
levels [8-11]. These GWAS clearly signal the LDLR as a
candidate gene for PH. As an example, the minor allele
of the rs6511720 polymorphism in LDLR was associated
with a reduction of 6.99 mg/dl in total cholesterol levels
[12] and this variant has been included in the LDL-C
gene score proposed by Talmud, however its functional-
ity is still unknown [6].
Cis-regulatory sequences control when, where, and
with what intensity genes are expressed [13]. Genetic
variation in these regions that influence gene expression
are widespread in the human genome and are respon-
sible for most of the inter-individual variability of nor-
mal phenotypes, but also for complex and polygenic
diseases [14-18]. Various rare mutations in the promoter
region of LDLR have been characterized in subjects with
FH [19-22]. However, whether or not common genetic
variants in the regulatory region of LDLR are associated
with non-FH primary hypercholesterolemia had not been




The PH group was composed of 477 unrelated subjects
recruited at two lipid clinics and a large car factory in-
volved in a prospective study of cardiovascular health
named Aragon Workers’ Health Study (AWHS). The
three centers are located in north-eastern Spain, and the
population groups involved share the same genetic back-
ground. Participants were selected according to thefollowing criteria, absence of prior cardiovascular disease,
LDL-C ≥ 90th percentile of a Spanish reference population
[23], triglyceride levels ≤ 200 mg/dl, BMI < 30 kg/m2, and
no mutations in the LDLR, APOB or PCSK9 genes. Sec-
ondary causes of hypercholesterolemia were excluded in
all subjects by clinical history and blood tests. A normoli-
pemic group of 525 unrelated healthy individuals was se-
lected from the AWHS with LDL-C ≤ 90th percentile and
TG ≤ 200 mg/dl. Exclusion criteria for controls were the
same as those for PH cases, except that they were not
tested for FH-causing mutations and had not received
prior treatment with hypolipidemic drugs. All subjects
provided written consent to a protocol approved by the
ethical review boards of the two participating hospitals
and the Comité Ético de Investigación Clínica de Aragón,
CEICA, for AWHS subjects.
Clinical and laboratory characteristics
All subjects were assessed for family history of early-onset
coronary heart disease, clinical history, medication use,
demographic characteristics, adiposity measures, and car-
diovascular risk factors. Fasting blood for biochemical
profiles was drawn after ≥ 4 weeks without hypolipidemic
drug treatment.
Subjects were categorized as never smokers and current
or former smokers. Hypertension was defined as systolic
Blood Pressure (BP) ≥ 140 mm Hg, diastolic BP ≥ 90 mm
Hg, or current use of antihypertensive medication. Dia-
betes was defined as a fasting glucose level ≥ 126 mg/dL
on at least two occasions or treatment with anti-diabetic
agents.
Blood glucose, High-density lipoprotein cholesterol
(HDL-C), cholesterol and triglyceride levels were de-
termined by standard methods. LDL-C was estimated
as total cholesterol – HDL-C–TG/5. Apolipoprotein (apo)
B and lipoprotein(a) were determined in the lipid clinics
by using immunoturbidimetry (Unimate 3, Roche, Basel,
Switzerland) and by the nephelometry analyzer IMMAGE
800 (Beckman Coulter, USA) in AWHS subjects.
Genetic analyses
DNA was isolated from EDTA blood samples following
standard procedures. A molecular diagnosis of FH was
ruled out in all hypercholesterolemic subjects from the
lipid clinics by using the LIPOchip® genetic diagnostic plat-
form [24]. The LIPOchip® platform (v3 to v9.1) contains
the most frequent Spanish mutations and CNVs in LDLR,
APOB and 4 in PCSK9. According to the LIPOchip® proto-
col, the coding sequences, the intron-exon boundaries as
well as the promoter of the LDLR and part of the APOB
exon 26 were sequenced in those individuals with negative
results.
The variability of the regulatory region of the LDLR
gene was studied in 125 PH subjects. To this end, a 3.103
De Castro-Orós et al. BMC Medical Genomics 2014, 7:17 Page 3 of 8
http://www.biomedcentral.com/1755-8794/7/17Kb fragment of the LDLR gene [ENSG:00000130164],
including the promoter (from −625 to +2478, consid-
ering the A nucleotide from ATG as +1) was sequenced
(Additional file 1: Table S1).
In order to predict possible transcription changes due
to the presence of a variant, known SNPs located in the
3 Kb fragment upstream of the transcription initiation
site were analyzed with both MatInspector and CHIP
Mapper [25]. These in silico analyses reported four
SNPs, namely rs17242346, rs17242739, rs17248720 and
rs17249120, potentially involved in the LDLR regulation.
We genotyped these polymorphisms, located in the
LDLR 5’ promoter, by iPlex technology based on a Mas-
sARRAY® platform (Sequenom®, Valencia, Spain) in all
the PH (n = 477) and control (n = 525) subjects. The re-
producibility of this method was confirmed by obtaining
consistent genotypes in 16 replicated samples.
Electrophoretic mobility shift assays
Preparation of nuclear extracts from sub-confluent
HepG2 cell cultures and Electrophoretic Mobility Shift
Assays (EMSAs) were done as reported by Riancho et al.
[26]. The gel bands were analyzed in an ODYSSEY infra-
red imaging system (Li-Cor Biosciences, Lincoln, NE).
The relative affinity of each allele was analyzed by com-
peting it with increasing amounts of the unlabelled allele
that had shown stronger binding. The bands were quan-
tified and the affinities were calculated by representing
the inverse of band intensity versus the excess of un-
labelled oligonucleotide. A higher slope indicates lower
oligonucleotide-protein affinity. The experiment was per-
formed in triplicate to confirm results.
Plasmid construct
A fragment of 2457 bp of the LDLR promoter from
c.-2,335 to c.67 + 36 was amplified by Polymerase Chain
Reaction (PCR) from the DNA of individuals carrying
the g.3131C > T (rs17248720) variants in homozygosis,
g.3131C and g.3131 T alleles. The oligonucleotides
introduce a SacI and NheI restriction site on the 5’ and 3’
end of the amplified fragment, respectively. The PCR
product was digested with SacI and NheI and cloned
into the digested luciferase reporter gene vector pGL3-
Basic (Promega, Madison, WI). The identity of the LDLR
promoter within the cloned DNA fragment, the C or T
variant allele, and the absence of other polymorphisms
or mutations were verified by sequencing of the resulting
plasmid.
Cell culture and transient transfection
HepG2 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin and 100 μg/ml strepto-
mycin and transfected with a jetPEI™-Hepatocyte. As apositive control and for normalization pGL3-Basic and
pRL-TK plasmids (Promega, Madison, WI) were used. In
the first experiment we added either g.3131C_LDLR-
pGL3 or g.3131T_LDLR-pGL3. Cells were processed and
Luciferase assays performed as previously described in De
Castro-Orós et al. [21].
Statistical analyses
Data are presented as means ± Standard Deviation (SD)
for continuous variables (medians and interquartile
ranges for variables with a skewed distribution) and as
frequencies or percentages for categorical variables. Dif-
ferences in mean values were assessed by using unpaired
t-tests or the Mann–Whitney U-test, as appropriate.
Categorical variables were compared using χ2 test. Geno-
type prevalence was estimated as observed proportions.
First, all subjects were distributed into quintiles according
to the LDL-C levels; these groups were composed of 199
individuals. Second, the quintile distribution was made in
control subjects and in each group 105 subjects were in-
cluded. Quintiles distribution of T-carriers and T-allele
frequency for rs17248720 SNP in the LDLR gene were cal-
culated in control subjects according to LDL-C levels,
p-value was calculated by Chi-square test corrected by
Bonferroni. Bivariate logistic regression analysis was used
to determine the odds ratios (OR) and 95% confidence in-
tervals (CI) of LDLR genotypes in cases versus controls.
Regression coefficients (β) and multivariate logistic regres-
sion with the forward selection based on likelihood ratios
was used to examine the effect of LDLR genotypes on
LDL-C. Variables shown in Table 1 showing P values <
0.20 in the bivariate analysis were introduced in the
model. All analyses were performed with the Statistical
Package for the Social Sciences software, version 16.0
(SPSS Inc., Chicago, IL), with significance set at P < 0.05.
Results
Table 1 shows the clinical and biochemical characteris-
tics of study subjects. By study design, PH subjects dis-
closed higher levels of total cholesterol, LDL-C, and apo
B than controls, while triglycerides were similar between
groups. The sequencing of 3.103 Kb of the relevant
LDLR promoter region was carried out in 125 PH sub-
jects and only six (rs12981050, rs17242353, rs57217136,
rs59281581, rs60173709 and rs6511720) appeared with
frequencies for the minor allele between 0.012 and 0.085
(Additional file 2: Table S2).
We also analyzed four polymorphisms revealed by pre-
diction software [25,27] to be located in potential regula-
tory elements in the distal promoter. The minor allele
frequencies of these variants are shown in Table 2. All the
analyzed polymorphisms were compatible with Hardy-
Weinberg expectations. The analyzed SNPs rs17242346,
rs17242739 and rs17249120 presented a minor allele
Table 1 Characteristics of the hypercholesterolemic and normolipemic groups
Polygenic hypercholesterolemia (n=477) Normolipemics (n=525) P value*
Men (%) 57.4 90.9 < 0.001
Age (years) 51 (41-56) 51 (42-54) 0.004
BMI (kg/m2) 26 (24-28) 27 (25-29) < 0.001
Waist circumference (cm) 92 (84-98) 95 (88-101) < 0.001
Smoking status (%) 0.019
Active smokers 24.8 37.3
Non-smokers 49.9 37.0
Past smokers 25.3 25.7
Hypertension (%) 20.7 20.2 0.885
Laboratory variables (mg/dL)
Fasting glucose 91 (84-98) 94 (87-102) < 0.001
Total cholesterol 290 ± 42 202 ± 32 < 0.001
Triglycerides 108 (83-137) 100 (72-136) 0.019
HDL-cholesterol 53 (46-65) 53 (47-61) 0.026
LDL-cholesterol 207 (186-231) 127 (107-147) < 0.001
Lipoprotein(a) 29 (13-63) 19 (8-51) < 0.001
Apolipoprotein B 148 ± 27 97 ± 22 < 0.001
Data shown for quantitative variable when normal distribution are means ± SD or median and interquartile range for variables with non-normal distribution. Data
shown for qualitative variable are percentages. *Calculated by unpaired t-test or Mann–Whitney U–test, as appropriate.
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rs17242346 was more frequent in the control group.
One of the four variants, rs17248720, showed highly sig-
nificant (p < 0.00001) allelic distribution differences be-
tween the PH and normolipemic populations. In fact,
when the frequency was calculated separately within the
three hypercholesterolemic populations, all showed minor
allele frequencies significantly lower than those in the con-
trol group.
When control groups were distributed in quintiles (Q)
according to LDL-C levels the Q2 showed more T-allele
carriers than the Q3, Q4 and Q5 (0.371 > 0.352 > 0.267 >
0.200) (p < 0.05) (Table 3). When all study subjects were
distributed in quintiles we observed that this frequency
was higher in Q3 than Q4 and Q5 with an almost sig-
nificant p-value (Additional file 3: Table S3).
Table 4 shows the results of multivariable linear re-
gression analysis using LDL-C levels as the dependentTable 2 Polymorphisms analyzed in PH and normolipemic po
Polygenic hyperch
Polymorphisms Zaragoza N=252 Barcelona N=127
rs17242346 (g.3724G>A) 0.107 0.071
rs17242739 (g.3627C>A) 0.000 0.008
rs17248720 (g.3131C>T) 0.090 0.083
rs17249120 (g.4440G>A) 0.004 0.000
AWHS, Aragon Workers’ Health Study. Zaragoza, Barcelona and AWHS were the thre
χ2 test. Genotype prevalences were estimated as observed proportions.variable. The variables that were independently associated
with LDL-C were lipoprotein(a) concentration, LDLR
g.3131C > T, and age, in this order, explaining together
10% of its variability in men. The results were similar
when all study subjects were considered and did not sub-
stantially differ when triglycerides, HDL-C, fasting glu-
cose, and waist circumference were forced into the model.
The age- and gender-adjusted OR of disclosing PH
for subjects bearing the LDLR g.3131 T allele was 0.478
(IC 0.342-0.667, p < 0.001).
To find out whether the C to T change alters the abil-
ity of the polymorphism region to bind transcription fac-
tors, we performed an EMSA using oligonucleotides
specific for each variant. The results (Figure 1A) showed
noticeable differences in affinity for nuclear proteins be-
tween the two alleles. After the binding was competed
with increasing amounts of an unlabelled oligonucleotide
corresponding to allele C, the inverse of the intensity ofpulations by iPlex technology
olesterolemia Controls
AWHS N=98 Total N=477 AWHS N=525 P value
0.122 0.100 0.080 0.113
0.000 0.000 0.000 0.280
0.102 0.090 0.160 < 0.0001
0.020 0.003 0.010 0.082
e hypercholesterolemic populations analyzed. Variables were compared using
Table 3 LDL cholesterol quintile distribution of frequencies of genotypes CT and TT and T-allele frequency for
rs17248720 polymorphism in LDLR gene in Control subjects
Q1 Q2 Q3 Q4 Q5 p
LDL-C 86 (77.5-95.0) 112 (107-116) 127 (124-131) 143 (139-147) 163 (155-168)
(mg/dl)
CT+TT genotype 0.324 0.371 0.352 0.267 0.200 0.046
T-allele frequency 0.176 0.195 0.195 0.143 0.109
LDL-C, LDL cholesterol measured by median and interquartiles. p: p-value was calculated by Chi-square test and corrected by Bonferroni.
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labelled oligonucleotide. The result (Figure 1B) indicated
that the T allele was easily displaced from the protein-
DNA complex (slope 0.0073 vs 0.004).
In order to test if the different affinity between vari-
ants influences the transcription of the LDLR gene, two
constructs carrying both variants of SNP g.3131C > T
were transfected in HepG2 cells. In comparison with cells
transfected with the g.3131C allele, those having the
g.3131 T construct showed a significant increase of 2.5
times (p < 0.01) of transcriptional activity (Figure 1C).
Discussion
In this study we used the novel approach of searching
for common polymorphisms located in the 5’UTR region
of the LDLR that might be involved in the pathogenesis
of primary hypercholesterolemia because of their pos-
sible influence in the transcription of the LDLR gene.
The major conclusions drawn from this study are that,
the LDLR g.3131C > T polymorphism in the 5’ region of
the LDLR is responsible for a major effect on LDL-C
concentration because of the increase in the transcrip-
tional activity of the LDLR gene, and also indicates that
the LDLR variation is associated with PH.
It has been shown that 58.9% of the variants involved
in regulation changes are located within the first 500 bp
upstream of the transcription start site, but 12.8% areTable 4 Variables independently associated with
LDL-cholesterol concentration by multivariate lineal
regression analysis*
Variables Standardizedcoefficient (β) P Adjusted R
2
Men
Lipoprotein(a), mg/dL 0.190 < 0.001 0.039
LDLR g.3131C > T, yes/no -0.179 < 0.001 0.070
Age, years 0.177 < 0.001 0.100
All study subjects
Age, years 0.236 < 0.001 0.054
Lipoprotein(a), mg/dL 0.172 < 0.001 0.083
LDLR g.3131C > T, yes/no -0.146 < 0.001 0.103
*Variables allowed to enter the model were those with P values < 0.20 in the
bivariate analysis.more than 1 kb upstream and show transcription factor
switching, with each allele having a higher affinity for a
different transcription factor [15,28]. As the LDLR pro-
moter is well-conserved in most of its positions among
chimps and humans, the sequencing of a 3103 pb frag-
ment, from −625 to +2478 of the ENSG00000130164
reference, showed only 6 variants, all located within the
first and second introns of the LDLR gene and with ≤
8.5% minor allele frequency.
Simultaneously to the sequencing of the LDLR pro-
moter we analyzed four polymorphisms that appeared to
be relevant in the regulation of LDLR expression accord-
ing to the bioinformatics analysis. We found that only
the variant g.3131C > T had a different distribution of
genotypes between a control group of 525 individuals
carefully selected among a working population of 1137
subjects and a group of 477 hypercholesterolemic individ-
uals without known FH-causing mutations (p < 0.00001).
A lower frequency of the minor T allele of this SNP
was observed in the total hypercholesterolemic popu-
lation and also in each of the three subgroups taken
separately. Surprisingly, the T-allele is also the ances-
tral one, as it has been observed by sequence comparison
between 20 eutherian mammals, and, according to our
results, this allele would have a protective effect against
hypercholesterolemia.
The g.3131C > T is placed in a large linkage disequilib-
rium (LD) block. In this work we had sequenced this LD
region in 125 subjects, including the rs6511720 SNP, and
we have calculated the LD between these SNPs (r2 = 0.211
and D’ = 0.487) not observing an association in this group.
A limitation to the study would be the diagnosis with
the LIPOchip® in the PH subjects as non-carriers of FH
causal mutations. It would be remotely possible to have
missed a variant located in a region not sequenced with
this platform, although coefficients for specificity and sen-
sitivity are 99.7% and 99.9%, respectively [29]. Another
limitation to the study is the different gender distribution
in the PH and control groups. However, regression ana-
lyses in men and in the overall population showed a similar
independent inverse association of the LDLR g.3131C >T
variant with LDL-C that, together with the lipoprotein(a)
concentration and age, explained ≈ 10% of LDL-C vari-
ability. The increase of the ancestral (and minor) allele
Figure 1 (See legend on next page.)
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Figure 1 Functional assays for g.3131C > T SNP (rs17248720). A) EMSA assay carried out with probes containing the C or T allele for the
g.3131 SNP (rs17248720) in the LDLR gene. NE, no HepG2 extract added. E, nuclear extract from HepG2 was added, ×10, ×20, ×50 and ×100 mean 10,
20, 50 and 100 times excess of unlabelled C-allele oligonucleotide. B) The inverse of band densities from the EMSA shown in Figure 1A were plotted
against the excess of unlabelled allele C oligonucleotide. C) Influence of g.3131C > T (rs17248720) variant on LDLR promoter strength in transient
transfection assay in FBS supplemented media. Fragments containing, none, either C or T allele were cloned in the promoterless plasmid pGL3-Basic
and transfected to FBS supplemented media cultures of HepG2. Measurements of luciferase activity were assayed in cell extracts 36 h after transfection.
The results were expressed as the media of three experiments carried out in triplicate considering pGL3-Basic expression as value 1.
De Castro-Orós et al. BMC Medical Genomics 2014, 7:17 Page 7 of 8
http://www.biomedcentral.com/1755-8794/7/17frequency in populations with a lower concentration of
LDL-C comparing to PH group and in replication cohorts
suggests that T-allele of the g.3131C > T variant in the
LDLR gene protects against hypercholesterolemia. This
observation might be explained by the lower affinity of the
g.3131 T variant for some repressors of LDLR gene tran-
scription, and as a consequence, it would increase the
transcriptional activity of the LDLR gene comparing with
the wild-type allele (Figure 1).
Taking together the genetic analyses and the functional
assays, our results suggest that the ancestral and minor
allele T at g.3131C > T is associated with LDL-C levels and
explains part of the LDL-C variability. This variant is lo-
cated in a regulatory element, and the shift of nucleotide
C to T produce a change in the affinity for transcription
factors as well as an increase of 2.5 times in the transcrip-
tional activity of the LDLR gene explaining the protective
effect of the T allele. Further studies aimed to expand
knowledge on the regulatory elements in the distal re-
gion of the LDLR promoter are warranted. Future studies
should also consider the effect of this variant on the
LDL-C response to lipid-lowering drugs or lifestyle changes.
The association of the rs17248720 polymorphism with
hypercholesterolemia confirms previous observations
from GWAS suggesting that non-coding variants located
at the LDLR locus are associated with blood lipid levels,
including LDL-C [8,9,12,13]. While studies attempt to find
new loci implicated in the hereditability of lipid levels, the
strongest locus associated with LDL-C continues to be
that containing the LDLR gene [10].
Conclusions
We have identified a variant located in the distal promoter
of the LDLR gene, g.3131C >T (rs17248720) that would ex-
plain part of the variability o the LDL cholesterol levels.
The ancestral T-allele at this site plays a protective role
against hypercholesterolemia by changing the affinity of this
region for transcription factors leading to an increase of 2.5
times in the transcriptional activity of the LDLR gene.Additional files
Additional file 1: Table S1. Primers designed for sequencing a 3.103
Kb fragment from the -625 to +2478 position in the LDLDR gene.Additional file 2: Table S2. Frequencies of variants in the regulatory
region of LDLR found in 125 PH subjects by sequencing.
Additional file 3: Table S3. LDL cholesterol quintile distribution of
frequencies of genotypes CT and TT and T-allele frequency for
rs17248720 polymorphism in LDLR gene in all study subjects.
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